New combo aims to shrink head and neck tumors before surgery
NCT ID NCT07400094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether giving a combination of the immunotherapy drug camrelizumab and two chemotherapy drugs (paclitaxel and carboplatin) before surgery can improve outcomes for people with advanced oral cavity or larynx cancer. Fifty participants will receive three cycles of the drug combo, then undergo surgery to remove the tumor. The study will measure how many tumors completely disappear or shrink significantly, and track survival over three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab (an immunotherapy drug) combined with paclitaxel and carboplatin (chemotherapy drugs)
What this could lead to
If successful, this approach could shrink tumors before surgery, potentially improving long-term survival and reducing the need for additional treatments after surgery.
What could go wrong
This is a small, early-phase study (50 people) with no control group, so results may not be definitive. Immunotherapy can cause serious side effects like inflammation of organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE LARYNX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
P.A. Hertsen Moscow Oncology Research Institute
Moscow, Russia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact